Lyell Immunopharma (LYEL) FCF Margin (QoQ) (2020 - 2026)

Lyell Immunopharma (LYEL) FCF Margin (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Lyell Immunopharma 276.08 Mn 276.08 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -137.94 Mn
Dec 31, 2025 -36.28 Mn
Sep 30, 2025 24.62 Mn
Jun 30, 2025 35.02 Mn
Mar 31, 2025 -35.72 Mn
Dec 31, 2024 -32.28 Mn
Sep 30, 2024 18.90 Mn
Jun 30, 2024 110.83 Mn
Mar 31, 2024 -106.83 Mn
Dec 31, 2023 -19.23 Mn
Sep 30, 2023 760,830.00
Jun 30, 2023 -7.50 Mn
Mar 31, 2023 -7.34 Mn
Dec 31, 2022 177.48 Mn
Sep 30, 2022 -177.47 Mn
Jun 30, 2022 853,883.00
Mar 31, 2022 -536,688.00
Dec 31, 2021 -242,197.00
Sep 30, 2021 14,308.00
Jun 30, 2021 90,127.00